Dasatinib

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Dasatinib

Examples of brand names: Sprycel [EU/DE]

ATC code: L01EA02

Main use (for orientation): Leukaemias

Documented research summary

CBD/dasatinib showed synergy in A549 cells and a xenograft model, not in clinical testing. The fetal lung model with dasatinib plus quercetin is a multi-substance rescue experiment, not isolated evidence of a human drug interaction.

Uncertainties and limitations

Single-ingredient oral dasatinib preparation for human use.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0180

Type of result: Preclinical evidence

Observation: Synergistic apoptosis (ZIP>10 in vitro) and an enhanced antitumour effect in the xenograft model.

Mechanism: SRC/PI3K/AKT

Study type: Cell and, where applicable, animal experiment; abstract assessed

Context studied: A549 cells and a mouse xenograft with low-dose dasatinib.

Clinical interpretation: Experimental finding; no clinical treatment or dose recommendation

Limitations and uncertainties: No human study; no clinical safety or suitable dosage inferred.

Original sources for this finding: Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC/PI3K/AKT signal pathway. [BMED38503236]

CBD/THC plus nicotine (multi-substance exposure) – laboratory and animal studies

Finding ID: B0181

Type of result: Preclinical evidence

Observation: Dasatinib/quercetin reduced senescence/interferon signals after combined cannabinoid/nicotine exposure.

Mechanism: Senolytic rescue with dasatinib plus quercetin

Study type: Cell and, where applicable, animal experiment; abstract assessed

Context studied: Human fetal lung explants at 10–16 weeks of gestation, ex vivo.

Clinical interpretation: Experimental finding; no clinical treatment or dose recommendation

Limitations and uncertainties: Not an isolated dasatinib–CBD pair; no pregnancy treatment or human drug interaction demonstrated.

Original sources for this finding: Co-exposure to cannabinoids and nicotine increases senescence in prenatal human lung development. [BMED42414534]

References and access status

[V2_LABEL_D0368] DASATINIB (DASATINIB) TABLET, FILM COATED DASATINIB (DASATINIB) TABLET, FILM COATED [BIOCON PHARMA INC.]

Original source / bibliographic reference

Authors: Biocon Pharma Inc.

Year: 2025

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED38503236] Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC/PI3K/AKT signal pathway.

Original source / bibliographic reference

Authors: Ye Q, Gui C, Jin D, Zhang J, Zhang J, Ma N, Xu L.

Year: 2024

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.biopha.2024.116445

PMID: 38503236

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED42414534] Co-exposure to cannabinoids and nicotine increases senescence in prenatal human lung development.

Original source / bibliographic reference

Authors: El Alam I, Belgacemi R, Hoarau A, Le Saux CJ, Glass I, Zana-Taieb E, Rehan VK, Prakash YS, Pabelick C, Danopoulos S, Al Alam D.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.1038/s41390-026-05037-w

PMID: 42414534

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility